Chronic-disease medicine: find the older-patient evidence gap
Real sources · Illustrative request · Sample version
Customer question
A fictional team wants to extend medical materials for one chronic-disease medicine to older patients with comorbidities.
Which patient claims do pivotal studies support, and where should the next research budget go?
Check age distribution, organ function and concomitant medicines first. A favourable overall result does not resolve an understudied subgroup.
Target patients versus available evidence
| Check / stage | Chart content |
|---|---|
| Target patients | Age over 75, comorbidities and common co-medication; client to confirm |
| Age coverage | Trial age distribution not supplied; key missing item |
| Safety and dose | Locate evidence by renal function, comorbidity and medication |
| Claim boundary | Separate overall results, subgroup findings and extrapolation |
Missing items are illustrative. The FDA draft informs fields; it is not a product compliance or efficacy finding.
Analysis excerpt
| Check | Finding / sample content | Use |
|---|---|---|
| Claim C01 | “Suitable for all older patients with comorbidities” exceeds the illustrative materials | Obtain age/comorbidity distributions before reviewing wording |
| Research priority | Target-population coverage is missing before another favourable article list | Separate material retrieval, additional analysis and a new study |
Delivery manifest
| File | Format | Contents |
|---|---|---|
| product-evidence-map.xlsx | XLSX | Patients × claims × studies × source locations; favourable, negative and uncertain findings separately. |
| claim-gap-brief.pdf | Claim boundaries and evidence priorities for one indication and one comparator. | |
| review-questions.docx | DOCX | Question sheet for one discussion: material owner, next step and acceptance fields per gap. |
This is an illustrative formal delivery manifest. This pack supplies an HTML report, CSV tables and a source register. Agree formal formats, quantities and scope in the quote.
Acceptance criteria
- Favourable, unfavourable and uncertain findings are recorded. Public evidence and product materials are labelled separately; each claim links to its sources and limitations.
Sources
- FDA: Geriatric information in prescription drug labeling (draft)
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/geriatric-information-human-prescription-drug-and-biological-product-labeling-guidance-industry